vTv Therapeutics reports positive topline data from Phase II trial of TTP273 to treat Type 2 diabetes


US-based clinical-stage biopharmaceutical company vTv Therapeutics has reported positive topline results from its Phase II trial of TTP273 to treat Type 2 diabetes.

TTP273 is an orally administered small molecule that activates the GLP-1 receptor, boosting insulin secretion and resulting in suppression of glucagon production and decreased food intake.

vTv Therapeutics Scientific Advisory Board member and Duke University endocrinology, metabolism, and nutrition division director department of medicine professor David D’Alessio said: “The convenience of an oral and well-tolerated GLP-1R therapy has the potential to meaningfully expand the treatment options for patients with Type 2 diabetes.”

The Phase II trial was conducted for 12 weeks across 30 sites in the US, and treated 174 patients with Type 2 diabetes who were on stable doses of metformin.

During the trial, the patients were randomised to receive either TTP273 at doses of 150mg once or twice daily or placebo.

"The convenience of an oral and well-tolerated GLP-1R therapy has the potential to meaningfully expand the treatment options for patients with Type 2 diabetes."

Results suggested that patients treated with placebo experienced an increased level of HbA1c than compared to TTP273.

Additionally, patients experienced weight loss while being treated with TTP273 in the once-daily and twice-daily arms.

vTv Therapeutics president and CEO Steve Holcombe said: “These positive data results further validate our novel approach to drug discovery.

“Based on these results, vTv will continue to advance development of TTP273 and enter discussions with potential partners to bring forward this important potential new therapy for patients with Type 2 diabetes.”

Researchers are continuing to analyse the overall study results.